What antiemetic regimen should be given with temozolomide?

Antiemetic Regimen for Temozolomide

For temozolomide at doses >75 mg/m²/day, give a 5-HT3 receptor antagonist (preferably ondansetron 8 mg or granisetron 1-2 mg) on an empty stomach 30 minutes before temozolomide, with optional addition of dexamethasone 8 mg for enhanced control.

Emetogenic Classification

Temozolomide's emetogenic potential depends on the dosing regimen:

• Low emetogenic risk: ≤75 mg/m²/day (concurrent with radiation)
• Moderate emetogenic risk: >75 mg/m²/day (adjuvant dosing at 150-200 mg/m²/day) 1

The FDA label explicitly states that antiemetic therapy may be administered prior to and/or following temozolomide administration, and recommends taking the drug on an empty stomach to reduce nausea and vomiting 2.

Recommended Antiemetic Regimens

For Adjuvant Temozolomide (150-200 mg/m²/day for 5 days)

Primary recommendation:

• 5-HT3 antagonist (choose one):
  • Ondansetron 8 mg PO twice daily, OR
  • Granisetron 2 mg PO once daily, OR
  • Palonosetron 0.5 mg PO once (day 1 only)
• Plus dexamethasone 8 mg PO/IV (day 1, with optional continuation on days 2-3 for delayed nausea) 3, 1

The 2017 ASCO guidelines classify moderate-risk agents as requiring a two-drug combination of a 5-HT3 antagonist (day 1) and dexamethasone (day 1) 3. For oral chemotherapy agents with moderate emetic risk like temozolomide, prophylaxis with oral 5-HT3 antagonists is specifically recommended 1.

For Concurrent Temozolomide (75 mg/m²/day with radiation)

Primary recommendation:

• Dexamethasone 8 mg PO/IV as a single agent, OR
• Prochlorperazine 10 mg PO every 6 hours PRN, OR
• Metoclopramide 20-30 mg PO three times daily 3, 1

Since the concurrent dose falls into the low emetogenic category, a single agent is typically sufficient 3.

Timing and Administration

• Administer antiemetics 30 minutes before temozolomide
• Take temozolomide on an empty stomach (bedtime administration may be advised) 2
• For 5-day cycles: Continue 5-HT3 antagonist daily during chemotherapy
• Palonosetron exception: Only give on day 1 (has longer half-life) 1, 4

Enhanced Regimens for Refractory Cases

If standard prophylaxis fails, consider:

1. Add olanzapine: Recent research shows ondansetron plus olanzapine significantly reduces moderate-to-severe nausea (grade ≥2) compared to ondansetron alone or ondansetron plus domperidone 5

2. Palonosetron-based regimen: A single 0.25 mg IV dose of palonosetron before 5-day temozolomide cycles achieved 91% complete response rates (0-168 hours) in patients already receiving dexamethasone 4

3. NK1 receptor antagonist: While not standard for moderate-risk agents, aprepitant can be added for select patients with persistent symptoms, following the high-risk dosing schedule 3, 6

Critical Pitfalls to Avoid

• Don't skip prophylaxis: The FDA label notes nausea/vomiting as expected toxicities requiring dose modification only for grade 3-4 severity 2
• Don't use PRN-only dosing: Around-the-clock antiemetic administration is superior to as-needed dosing for multi-day chemotherapy 7
• Monitor delayed phase: Moderate/severe nausea frequently occurs during the delayed phase (days 2-5) with temozolomide, especially in females and patients with low lymphocyte counts 8
• Account for concomitant dexamethasone: Many glioblastoma patients already receive dexamethasone 2-8 mg/day for cerebral edema, which provides baseline antiemetic coverage 4

Special Considerations

For multi-day regimens: Antiemetics appropriate for the emetic risk should be given each day during chemotherapy and for 2 days after completion 3, 9

Adjunctive agents: Lorazepam 0.5-2 mg every 4-6 hours can be added for anxiety or anticipatory nausea, but should not be used as monotherapy 3, 1